rla-0 Antibody

What is the target protein of RLA-0 antibody and what is its biological significance?

RLA-0 antibody (also known as anti-RPLP0) specifically targets the ribosomal protein lateral stalk subunit P0 (RPLP0), a critical component of the 60S ribosomal subunit. RPLP0 is the functional equivalent of the bacterial L10 ribosomal protein and belongs to the L10P family of ribosomal proteins. Its biological significance lies in its essential role in protein synthesis, where it forms part of the ribosome's lateral stalk structure .

RPLP0 is characterized as a neutral phosphoprotein with a C-terminal domain nearly identical to the C-terminal regions of the acidic ribosomal phosphoproteins P1 and P2. Importantly, RPLP0 can interact with P1 and P2 to form a pentameric complex consisting of P1 and P2 dimers and a P0 monomer, which is crucial for ribosomal function and protein translation .

While primarily known for its role in translation, RPLP0 has gained research interest due to its potential involvement in various cellular processes beyond protein synthesis, making antibodies against this protein valuable tools in multiple research contexts.

What experimental applications are suitable for RLA-0 polyclonal antibody?

RLA-0 polyclonal antibody is optimized for several key experimental applications with established protocols:

• Western Blotting: The antibody effectively detects endogenous levels of RPLP0 protein in Western blot applications, with recommended dilutions ranging from 1:500 to 1:2000 . This makes it suitable for analyzing RPLP0 expression across different experimental conditions or comparing expression levels between different tissues or cell types.

• ELISA: The antibody can be utilized in enzyme-linked immunosorbent assays with recommended dilutions of 1:5000 to 1:20000 , enabling quantitative assessment of RPLP0 levels in various sample types.

Although not explicitly mentioned in the product specifications, polyclonal antibodies against ribosomal proteins can potentially be adapted for other immunological techniques such as immunoprecipitation, immunofluorescence microscopy, or immunohistochemistry, though optimization would be required for these applications.

What is the species reactivity profile of RLA-0 antibody?

RLA-0 polyclonal antibody demonstrates cross-species reactivity with RPLP0 from multiple mammalian species, specifically:

• Human

• Mouse

• Rat

This multi-species reactivity makes the antibody valuable for comparative studies across different model organisms. The cross-reactivity is likely due to the high conservation of ribosomal proteins across mammalian species, particularly in functional domains. The antibody was developed using a synthesized peptide derived from the human RPLP0 protein sequence at amino acid range 240-320 , which represents a region with high sequence homology across these species.

When planning experiments with other species not listed in the reactivity profile, researchers should conduct preliminary validation studies to confirm reactivity before proceeding with full-scale experiments.

What are the optimal protocols for using RLA-0 antibody in Western blotting?

For optimal Western blot results with RLA-0 polyclonal antibody, consider the following methodological approach:

Sample Preparation:

• Prepare whole cell lysates using a standard lysis buffer containing protease inhibitors

• Typical protein loading: 10-30 μg per lane depending on expression level

• Denature samples at 95°C for 5 minutes in loading buffer containing SDS and reducing agent

Electrophoresis and Transfer:

• Resolve proteins on 10-12% SDS-PAGE (RPLP0 has a molecular weight of approximately 34 kDa)

• Transfer to PVDF or nitrocellulose membrane using standard wet or semi-dry transfer systems

Antibody Incubation:

• Block membrane with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

• Dilute RLA-0 antibody in blocking buffer at 1:500-1:2000 as recommended

• Incubate with primary antibody overnight at 4°C with gentle rocking

• Wash 3-5 times with TBST

• Incubate with appropriate HRP-conjugated secondary antibody (anti-rabbit IgG) at manufacturer's recommended dilution

• Wash 3-5 times with TBST

Detection:

• Apply ECL substrate and image according to standard protocols

• Expected band: ~34 kDa corresponding to RPLP0

Include appropriate positive controls from human, mouse, or rat samples since the antibody has demonstrated reactivity with these species .

How should RLA-0 antibody be stored to maintain optimal activity?

Proper storage of RLA-0 polyclonal antibody is critical for maintaining its binding capacity and specificity over time:

• Store at -20°C for long-term stability (up to 1 year as specified by the manufacturer)

• The antibody is supplied as a liquid in PBS containing 50% glycerol and 0.02% sodium azide

• Avoid repeated freeze-thaw cycles by aliquoting the antibody into single-use volumes upon receipt

• When handling, keep the antibody on ice or at 4°C

• Return to -20°C promptly after use

• Monitor for signs of degradation such as decreased signal intensity or increased background

For working solutions, store at 4°C and use within 1-2 weeks. If extended storage of diluted antibody is necessary, add stabilizing proteins such as BSA (0.1-1%) and preservatives to prevent microbial growth.

What validation methods are recommended to confirm RLA-0 antibody specificity?

Rigorous validation of RLA-0 antibody specificity is essential to ensure experimental reliability. Consider implementing the following validation strategies:

Positive and Negative Controls:

• Include tissue or cell lines known to express RPLP0 (virtually all cells should express this ribosomal protein)

• If possible, test RPLP0-knockdown or knockout samples as negative controls

Peptide Competition Assay:

• Pre-incubate the antibody with excess immunizing peptide (the manufacturer used a synthetic peptide from amino acids 240-320 of human RPLP0)

• Run parallel Western blots with blocked and unblocked antibody

• Specific signals should be abolished or significantly reduced in the peptide-blocked sample

Multiple Detection Methods:

• Confirm findings using different detection techniques (Western blot, ELISA, immunofluorescence)

• Verify results with alternative antibodies targeting different epitopes of RPLP0

Molecular Weight Verification:

• Confirm that the detected band corresponds to the expected molecular weight of RPLP0 (~34 kDa)

The manufacturer states that the RLA-0 polyclonal antibody has been verified to detect endogenous levels of the target protein , suggesting that basic validation has been performed, but researchers should conduct their own validation in their specific experimental systems.

What are common issues when using RLA-0 antibody in immunoassays and how can they be resolved?

When working with RLA-0 antibody, researchers may encounter several technical challenges. Here are common issues and their solutions:

High Background Signal:

• Issue: Non-specific binding resulting in high background noise

• Solutions:

  • Increase blocking time/concentration (try 5% BSA instead of milk for phospho-proteins)

  • Optimize antibody dilution (test ranges from 1:500 to 1:2000 for Western blot)

  • Increase washing frequency and duration

  • Filter antibody solutions before use to remove any precipitates

Weak or No Signal:

• Issue: Insufficient target protein detection

• Solutions:

  • Decrease antibody dilution (use more concentrated, e.g., 1:500)

  • Increase incubation time or temperature

  • Enhance detection sensitivity with amplification systems

  • Verify protein loading and transfer efficiency

  • Check sample preparation (ensure protease inhibitors are used)

Multiple Bands:

• Issue: Detection of non-specific proteins or degradation products

• Solutions:

  • Optimize SDS-PAGE conditions for better resolution

  • Verify sample integrity (minimize freeze-thaw cycles)

  • Include protease inhibitors in lysis buffers

  • Perform peptide competition assay to identify specific bands

Inconsistent Results:

• Issue: Variability between experiments

• Solutions:

  • Standardize protocols rigorously

  • Aliquot antibody to avoid freeze-thaw cycles

  • Prepare fresh working solutions for each experiment

  • Include internal loading controls for normalization

How do crossreactivity issues with RLA-0 antibody compare to other antibodies targeting ribosomal proteins?

Crossreactivity is an important consideration when working with antibodies against ribosomal proteins like RPLP0. Understanding this in context:

Ribosomal proteins often share structural similarities and conserved domains, which can lead to crossreactivity issues. In the case of RLA-0 polyclonal antibody, it was developed against a specific region (amino acids 240-320) of human RPLP0 , which helps to minimize potential crossreactivity with other ribosomal proteins.

Comparative studies with other antibodies targeting related proteins can provide valuable insights:

• Structural Homology Considerations:

  • RPLP0 shares C-terminal similarity with RPLP1 and RPLP2 , creating potential for crossreactivity

  • Unlike antibodies targeting highly conserved ribosomal proteins, RLA-0 targets a more distinct region

• Species-Specific Crossreactivity:

  • While RLA-0 antibody is reactive with human, mouse, and rat RPLP0 , its crossreactivity profile differs from antibodies targeting other ribosomal proteins

  • Immunological studies have shown that antibodies to other ribosomal components can display variable crossreactivity patterns across species

• Validation Approaches:

  • Similar to approaches used with anti-Sm and anti-RNP antibodies in rheumatology , solid-phase immunoassays can be employed to assess RLA-0 specificity

  • Western blot analysis using recombinant RPLP0, RPLP1, and RPLP2 can help quantify potential crossreactivity

The affinity purification process used in producing RLA-0 antibody (using epitope-specific immunogen) helps reduce potential crossreactivity compared to non-purified antisera against ribosomal proteins.

How can RLA-0 antibody be utilized in studying RPLP0's role in disease mechanisms?

RLA-0 antibody offers valuable capabilities for investigating RPLP0's involvement in various disease mechanisms:

Cancer Research Applications:

• RPLP0 expression levels can be monitored across different cancer types and stages using RLA-0 antibody in Western blot analyses at dilutions of 1:500-2000

• Immunohistochemical analysis of tumor samples can reveal RPLP0 localization patterns

• Co-immunoprecipitation experiments can identify disease-specific RPLP0 binding partners

Autoimmune Disease Investigations:

• Similar to studies of autoantibodies in rheumatic diseases , RLA-0 antibody can help investigate potential autoimmune responses against RPLP0

• Comparative analyses between normal and autoimmune samples can reveal modifications to RPLP0

Viral Infection Studies:

• Drawing on methodologies from SARS-CoV-2 antibody crossreactivity studies , researchers can investigate interactions between viral proteins and RPLP0 using RLA-0 antibody

• Western blot and co-localization immunofluorescence can reveal virus-induced changes in RPLP0 expression or localization

Neurodegenerative Disease Research:

• RLA-0 antibody can be employed to investigate potential alterations in ribosomal function in neurodegenerative conditions

• Brain tissue analysis using immunohistochemistry can reveal region-specific changes in RPLP0 expression

What methodological approaches can combine RLA-0 antibody with advanced proteomics techniques?

Integration of RLA-0 antibody with advanced proteomics creates powerful research methodologies:

Immunoprecipitation-Mass Spectrometry (IP-MS):

• Use RLA-0 antibody to immunoprecipitate RPLP0 and associated complexes

• Analyze protein interactions by mass spectrometry

• This approach can identify novel binding partners and post-translational modifications

• Protocol considerations: optimize antibody concentration and binding conditions; include appropriate controls to filter out non-specific interactions

Proximity Labeling Techniques:

• Combine RLA-0 antibody with BioID or APEX2 proximity labeling approaches

• Visualize proximal proteins in the RPLP0 microenvironment

• Methodological considerations: validate antibody compatibility with fixation conditions used in proximity labeling protocols

Cross-Linking Mass Spectrometry (XL-MS):

• Use RLA-0 antibody to validate cross-linking mass spectrometry data for RPLP0 interactions

• Confirm spatial relationships identified through XL-MS using immunofluorescence co-localization

Ribosome Profiling Applications:

• Employ RLA-0 antibody in ribosome profiling studies to investigate translational dynamics

• Correlate RPLP0 modifications with changes in translation efficiency

• Methodological consideration: validate antibody compatibility with ribosome profiling protocols

How does the immunogenicity profile of RLA-0 antibody compare with other antibodies targeting ribosomal proteins?

Understanding the immunogenicity characteristics of RLA-0 antibody in comparison to other anti-ribosomal protein antibodies provides valuable context for experimental design:

Epitope Recognition Patterns:

• RLA-0 polyclonal antibody recognizes epitopes within amino acids 240-320 of human RPLP0

• This region differs from the highly conserved C-terminal domain shared with P1 and P2 proteins

• Compared to antibodies targeting other ribosomal proteins, the epitope specificity influences cross-reactivity profiles

Host Immune Response Considerations:

• Generated in rabbit as host species , RLA-0 antibody exhibits immunogenic properties distinct from mouse-derived or other species-derived antibodies

• The polyclonal nature provides recognition of multiple epitopes within the target region, contrasting with monoclonal antibodies against other ribosomal proteins

Comparative Analysis with Autoantibodies:

• Studies of autoantibodies in rheumatic diseases demonstrate variable immunogenicity patterns

• Similar to anti-Sm and anti-RNP antibodies that show specific diagnostic value in systemic lupus erythematosus , RLA-0 antibody's immunogenic profile determines its research utility

• Unlike autoantibodies that may cross-react with multiple antigens, affinity-purified RLA-0 antibody offers enhanced specificity

Species Reactivity Profile:

• RLA-0 antibody's reactivity with human, mouse, and rat RPLP0 reflects conservation of epitopes across these species

• This cross-species reactivity profile differs from antibodies targeting less conserved ribosomal proteins

What emerging research areas could benefit from RLA-0 antibody applications?

RLA-0 antibody holds significant potential for advancing multiple emerging research frontiers:

Ribosome Heterogeneity Exploration:

• Using RLA-0 antibody to investigate potential variations in RPLP0 incorporation across different ribosome populations

• Combining with specialized ribosome purification techniques to identify tissue-specific or condition-specific RPLP0 modifications

• Methodological considerations: pair with subunit-specific markers to distinguish 60S subunit variants

Extra-Ribosomal Functions:

• Investigating potential moonlighting functions of RPLP0 beyond its canonical role in translation

• Using RLA-0 antibody in subcellular fractionation studies to identify non-ribosomal RPLP0 localizations

• Technical approach: combine with organelle-specific markers in co-localization studies

Stress Response Mechanisms:

• Studying RPLP0 modifications under various cellular stress conditions

• Monitoring RPLP0 involvement in stress granule formation using RLA-0 antibody immunofluorescence

• Research design consideration: create time-course experiments to track RPLP0 dynamics during stress induction and recovery

Specialized Ribosomes in Development:

• Exploring RPLP0 variations during embryonic and tissue development

• Using RLA-0 antibody in developmental studies across different model organisms (human, mouse, rat)

• Methodological approach: combine with developmental stage-specific markers to correlate RPLP0 changes with developmental processes

How could RLA-0 antibody be integrated into multi-omics experimental designs?

Strategic integration of RLA-0 antibody into multi-omics frameworks enables comprehensive system-level analyses:

Integrated Transcriptomics-Proteomics:

• Use RLA-0 antibody for RPLP0 protein quantification in parallel with RNA-seq for RPLP0 transcript analysis

• Correlate protein-level changes with transcriptional alterations

• Methodological consideration: ensure comparable sample preparation for both proteomic and transcriptomic analyses

Single-Cell Multi-Omics Applications:

• Combine RLA-0 antibody immunofluorescence with single-cell RNA-seq

• Investigate cell-to-cell variability in RPLP0 expression and its correlation with transcriptome profiles

• Technical approach: optimize immunostaining protocols compatible with single-cell isolation methods

Spatial Proteomics Integration:

• Utilize RLA-0 antibody in spatial proteomics approaches such as imaging mass cytometry

• Map RPLP0 distribution relative to other cellular components across tissue sections

• Research design: develop multiplexed antibody panels including RLA-0 antibody and complementary markers

Functional Genomics Correlation:

• Implement CRISPR screens targeting RPLP0 regulators and use RLA-0 antibody to assess resulting protein level changes

• Correlate genetic perturbations with RPLP0 expression and modification patterns

• Methodological consideration: design Western blot experiments at 1:500-2000 dilutions to quantify subtle changes in RPLP0 levels following genetic manipulation